GO
| HSI1 | 25,042.71 | +291.93 | 202.73B |
| HSCEI1 | 8,339.63 | +114.23 | 56.78B |
| Back Zoom + Zoom - Block Traded | |
|
2026-09-21 11:56:55 BofA Securities disclosed that it recently conducted a field study on China's healthcare industry in Shanghai, meeting with nine Chinese healthcare companies and an oncology expert. The broker learned that execution of pharmaceutical and biotechnology pipelines and growth in innovative drugs remain solid. Academic activities rebounded in 3Q, while the results of the National Reimbursement Drug List broadly met management expectations. The expert was positive on China's innovation outlook, believing that HARMONi trial data showed PD-1/VEGF bispecific antibodies may have potential advantages over traditional PD-1 therapies and could become the backbone of next-generation treatment. Besides, the expert also believed that safety and convenience of medication are key differentiating factors for ADC commercialization. BofA Securities maintained Buy ratings on INNOVENT BIO (01801.HK), HANSOH PHARMA (03692.HK), HENGRUI PHARMA (600276.SH), 3SBIO (01530.HK) and ANGELALIGN (06699.HK), with target prices of HKD140, HKD45.3, RMB65.8, HKD23.8 and HKD107.6 respectively. The broker raised the target price of SBP GROUP (01177.HK) from HKD7.1 to HKD7.3 and reiterated its Buy rating. It maintained an Underperform rating and target price of HKD8.6 on CSPC PHARMA (01093.HK). It also considered WUXI BIO (02269.HK) valuation to be demanding, maintaining a Neutral rating and target price of HKD56. ~ AASTOCKS Financial News Website: www.aastocks.com | |